Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma PatientsCamillo Porta, Mara De Amici, Lucia Sacchi et al.|Oncology|2012Cited by 78
Immunological Effects of Multikinase Inhibitors for Kidney Cancer: A Clue for Integration with Cellular Therapies?Camillo Porta, Paolo Pedrazzoli, Chiara Paglino et al.|Journal of Cancer|2011Cited by 37
Sunitinib in Advanced Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single Institution Retrospective StudyChiara Paglino, Camillo Porta, Ilaria Imarisio et al.|Future Oncology|2012Cited by 16
Tivantinib (ARQ197) in hepatocellular carcinomaCamillo Porta, Carlo Ganini, Palma Giglione et al.|Expert Review of Anticancer Therapy|2015Cited by 16
Lingual Metastasis from Renal Cell Carcinoma: A Case Report and Literature ReviewCarlo Ganini, Camillo Porta, Angioletta Lasagna et al.|Rare Tumors|2012Cited by 15